Harvard Bioscience (HBIO) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
6 Mar, 2026Opening remarks and agenda
Meeting called to order by the chairman, with formalities and agenda reviewed.
Voting procedures and eligibility requirements explained to stockholders.
Specific resolutions to be voted on
Proposal to amend the Certificate of Incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-15, ratio to be set by the board.
Proposal to approve adjournment or postponement of the meeting if more time is needed to solicit votes for the reverse stock split.
Corporate governance
Inspector of Election appointed and sworn in to oversee voting process.
Quorum confirmed, allowing the meeting to proceed with business.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Harvard Bioscience
- 2025 restructuring and margin gains set the stage for 2026 growth from new product innovation.HBIO
Q4 202512 Mar 2026 - Q2 2024 revenue fell nearly 20% with net loss widening, prompting reduced full-year guidance.HBIO
Q2 20242 Feb 2026 - Growth driven by new organoid and bioproduction systems, with APAC recovery boosting outlook.HBIO
Jefferies Global Healthcare Conference1 Feb 2026 - Shareholders to vote on a reverse stock split to maintain Nasdaq listing and flexibility.HBIO
Proxy Filing30 Jan 2026 - Up to 9.5 million shares registered for resale, with no direct proceeds to the company.HBIO
Registration Filing30 Jan 2026 - Approval sought for a reverse stock split to maintain Nasdaq listing and shareholder value.HBIO
Proxy Filing20 Jan 2026 - New product launches and bioproduction expansion set the stage for double-digit growth.HBIO
Sidoti September Small-Cap Virtual Conference20 Jan 2026 - Revenue and margins declined, but cost cuts and new products support cautious Q4 optimism.HBIO
Q3 202416 Jan 2026 - Organoid and bioproduction innovations drive double-digit growth and recurring revenues.HBIO
Sidoti Micro-Cap Virtual Conference9 Jan 2026